Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 297.33B |
| Revenue (ttm) | 63.49B |
| Net Income (ttm) | 9.43B |
| Shares Out | 850.32M |
| EPS (ttm) | 11.74 |
| PE Ratio | 29.64 |
| Forward PE | 17.10 |
| Dividend | 9.70 (2.79%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 820,770 |
| Average Volume | 1,098,121 |
| Open | 348.90 |
| Previous Close | 347.90 |
| Day's Range | 344.90 - 349.50 |
| 52-Week Range | 231.90 - 349.70 |
| Beta | 0.17 |
| RSI | 71.84 |
| Earnings Date | Jan 29, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial StatementsNews
Gold headed to $6,000 - Veteran investor tells us why
David Roche from Quantum Strategy shared his outlook on markets amid geopolitical tensions, forecasting Japan’s 10-year government bond yield to rise to 2.9% within a year as government debt increases...
Roche (RHHBY) Expands Investment in North Carolina Facility
Roche (RHHBY) Expands Investment in North Carolina Facility
Roche more than doubles investment in new North Carolina site
Genentech To Create Additional 100 Jobs With Further Investment In North Carolina Facility
(RTTNews) - Biotechnology company Genentech, a subsidiary of Roche Holding AG (RHHBY.PK), Tuesday announced an expansion of its initial investment in a new Holly Springs, North Carolina manufacturing ...
Roche's Genentech more than doubles investment in North Carolina facility to about $2 billion
Roche's Genentech said on Tuesday it will more than double its initial investment in a biomanufacturing facility in North Carolina to about $2 billion, as the companies look to further boost their $50...
Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced an expansion of its initial investment in a new Holly Springs, North ...
ClearBridge International Growth EAFE Strategy exits Novo Nordisk, adds Roche in Q4
Goldman Sachs Upgrades Roche (RHHBY) Amid Growth Prospects
Goldman Sachs Upgrades Roche (RHHBY) Amid Growth Prospects
Roche upgraded at Goldman Sachs on reduced catalyst risks
Goldman Sachs upgrades Roche (RHHBY) to neutral and raises price target to CHF365. Read more here.
BGI, Roche roll out diagnostic tests for Alzheimer's in China
BGI Genomics and Roche Diagnostics have rolled out tests for Alzheimer's disease in China, the companies said, in an effort to expand access to easier-to-use diagnosis and monitoring choices for patie...
ClearBridge Dividend Strategy Fund adds PCG, RHHBY, exits EIX, MRK among Q4 moves
The Zacks Analyst Blog Highlights Micron Technology, Roche and UnitedHealth
Micron Technology, Roche and UnitedHealth highlight diverging opportunities across technology, pharmaceuticals and managed care.
Top Stock Reports for Micron Technology, Roche & UnitedHealth
MU leads today's Zacks Research Daily, with AI-driven memory demand, strong DRAM pricing recovery and solid cash flow powering recent outperformance.
Iran will not fall because of the US: David Roche
David Roche from Quantum Strategy talks about the protests in Iran, and possibilities for regime change there. He explains why even if the US were to intervene in Iran, it would not fuel a regime chan...
What's Going On With Royalty Pharma Stock Wednesday?
Royalty Pharma plc (NASDAQ: RPRX) stock has gained around 53% year to date, as per data from Benzinga Pro . On Monday, Royalty Pharma acquired the final portion of PTC Therapeutics Inc.’s (NASDAQ: PT...
Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics
(RTTNews) - Royalty Pharma plc (RPRX) announced that it has acquired the final portion of PTC Therapeutics' remaining royalty interest in Roche's Evrysdi. The transaction includes an upfront payment o...
Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi
Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ: RPRX) today announced that it has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240...
Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy
Sanofi SA (NASDAQ: SNY) on Wednesday agreed to acquire Dynavax Technologies Corporation (NASDAQ: DVAX) for $15.50 per share in cash, reflecting a total equity value of approximately $2.2 billion. Th...
US Drug Pricing Deal May Lead to Swiss Medicine Price Hikes
US drug price cuts may push up the cost of new medicines in Switzerland, Roche's CEO warns.
Roche (RHHBY) CEO Predicts Drug Price Increase in Switzerland
Roche (RHHBY) CEO Predicts Drug Price Increase in Switzerland
Roche: FDA Approves Lunsumio VELO Under Accelerated Approval
(RTTNews) - Roche (RHHBY, RO.SW, ROG.SW) announced that the FDA has approved CD20xCD3 bispecific Lunsumio VELO or mosunetuzumab, as a subcutaneous formulation, for the treatment of adult patients with...
Roche CEO expects surge in drug prices in Switzerland after U.S. deal
Roche (RHHBY) CEO Thomas Schinecker stated that the recent U.S. drug pricing deals will likely lead to higher prices for new drugs in Switzerland.
FDA Approves Genentech's Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD...
Trump tariffs push Swiss pharma CEO to urge price alignment with US
Roche’s Chief Executive an interview with Swiss media published on Sunday called for Switzerland to pay more for new drugs, to bring prices in line with those paid by Washington. The Swiss pharmaceuti...